Contents

Search

mometasone furoate (Asmanex, Nasonex)

Tradename: Inhaled glucocorticoid (Asmanex). Indications: - maintenance prophylactic treatment of asthma in patients 12 years or older - chronic obstructive pulmonary disease - allergic rhinitis - atopy - inflammatory dermatoses - atopic dermatitis - seborrheic dermatitis - contact dermatitis - discoid lupus - granuloma annulare - psoriasis - anal pruritus - rash - lichen simplex chronicus - cutaneous T-cell lymphoma Contraindications: - acute episodes of asthma, including status asthmaticus Dosage: 1) start 220 ug (1 inhalation) QHS - 440 ug (2 inhalations) BID if on oral glucocorticoid 2) maximum 440 ug QD - 880 ug QD if on oral glucocorticoid 3) topical: apply 0.1% ointment/cream/lotion TID/QID. 'Twisthaler' device (dry powder inhaler) contains 30, 60 or 120 inhalations delivers 200 ug of mometasone furoate from the mouthpiece Nasonex nasal spray 1-2 whiffs QD (generic FDA-approved March 2016) [4] Pharmacokinetics: - maximum benefit may take 2 weeks or longer Adverse effects: 1) generally mild to moderate in severity 2) pharyngitis (8-13% vs 7% with placebo) 3) upper respiratory tract infections (8-5% vs 7% with placebo) 4) oral candidiasis (4-6% vs 2% with placebo) 5) growth suppression & decreased bone mineral density has been reported Drug interactions: - no significant drug interactions in clinical trials Mechanism of action: - inhaled glucocorticoid The average wholesale price is $155.75/120 inhalations. (2005)

Interactions

drug interactions drug adverse effects (more general classes) monitor with drug (more general classes)

Specific

Mometasone Topical

General

antipruritic agent glucocorticoid

Properties

MISC-INFO: pregnancy-category C safety in lactation ?

Database Correlations

PUBCHEM correlations

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996.
  2. Prescriber's Letter 12(9): 2005 Asmanex (Mometasone Furoate Inhalation Powder) Detail-Document#: 210906 (subscription needed) http://www.prescribersletter.com
  3. Deprecated Reference
  4. Apotex News Release. Mar 22, 2016 Apotex Launches First Generic Version of Merck's Nasonex http://www.prnewswire.com/news-releases/apotex-launches-first-generic-version-of-mercks-nasonex-573064911.html
  5. Department of Veterans Affairs, VA National Formulary

Component-of

ammonium lactate/lactate/mometasone ammonium lactate/mometasone clotrimazole/gentamicin/mometasone formoterol/fumarate/mometasone formoterol/mometasone (Dulera)